Choledocholithiasis With Cholecystitis With Obstruction, Cholelithiasis, Obstructive Jaundice, Pancreatitis
Conditions
Keywords
respiratory depression, The COMBO Endoscopy Oropharyngeal Airway, Hypoxia, Sedation, ERCP
Brief summary
Hypoxia represents the prevailing adverse occurrence during the sedation of patients undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) with propofol. A recent innovation in this domain is the COMBO Endoscopy Oropharyngeal Airway-a multifaceted device that encompasses capnography monitoring, bite block , oxygenation support, and oropharyngeal airway management. This device has been purposefully designed to cater to the unique requirements of endoscopic procedures. The principal objective of this study is to assess the efficacy of the COMBO Endoscopy Oropharyngeal Airway in reducing the incidence of hypoxia in patients undergoing ERCP under sedation.
Interventions
Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
Sponsors
Zhejiang University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years； * The ASA classification ranges from I to III. * Patients have signed the informed consent form. * Patients scheduled to undergo sedated ERCP examination; * The estimated duration of the procedure does not exceed 45 minutes.
Exclusion criteria
1. Patients with coagulation disorders, tendency for oral/nasal bleeding, mucosal injury/occupying lesions, or difficult oropharyngeal airway insertion making airway management unfeasible; 2. Severe cardiac dysfunction (\<4 METs); 3. Severe renal insufficiency (requiring preoperative dialysis); 4. Child-Pugh class C; 5. Diagnosed chronic obstructive pulmonary disease (COPD) or other acute/chronic pulmonary diseases requiring long-term/intermittent oxygen therapy; 6. Increased intracranial pressure; 7. Upper respiratory tract infections (oral/nasal/pharyngeal); 8. Fever (core temperature \>37.5°C); 9. Confirmed pregnancy or current breastfeeding; 10. Allergy to sedatives (e.g., propofol) or medical adhesives; 11. Emergency procedures; 12. Multiple trauma injuries; 13. Peripheral oxygen saturation (SpO2) levels below 95% while breathing room air preoperatively; 14. BMI \<18.5 or \>30 kg/m²; 15. Current participation in other clinical trials; 16. Other conditions deemed ineligible by investigators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of hypoxia | Patients will be followed for the duration of hospital stay, an expected average about 2 hours | 75% ≤ SpO2 \< 90% for \<60 s |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of sub-clinical respiratory depression | Patients will be followed for the duration of hospital stay, an expected average about 2 hours | 90% ≤ SpO2 \< 95% |
| The incidence of severe hypoxia | Patients will be followed for the duration of hospital stay, an expected average about 2 hours | SpO2 \< 75% or 75% ≤ SpO2 \< 90% for ≥60 s |
Other
| Measure | Time frame | Description |
|---|---|---|
| The incidence of other adverse events | Patients will be followed for the duration of hospital stay, an expected average about 2 hours | Other adverse events recorded by tools proposed by the World Society of Intravenous Anesthesia International Sedation Task Force |
Countries
China
Contacts
Primary ContactDiSan Head of Anesthesiology, PhD
Backup ContactLianjuan Sun, Master
Outcome results
None listed